Mark McDade

Mr. McDade is Co-founder and Managing Partner of the Qiming US Healthcare Fund, a venture capital firm based in Seattle and formed in January 2017. Prior to Qiming, from April 2008 until his retirement in October 2016, Mr. McDade was EVP and Chief Operating Officer at CICB S.A., a Belgian biopharmaceutical company. From 2002 to 2007, Mr. McDade served as Chief Executive Officer and a member of the board of directors of PDL Biopharma, Inc., a biotechnology company. From 2000 to 2002, Mr. McDade was Chief Executive Officer of Signature Bioscience, Inc., a drug discovery company. From 1994 to 2000, Mr. McDade served as Chief Operating Officer and a director of Corixa Corporation, a biopharmaceutical company he co-founded in Seattle. Prior to Corixa, Mr. McDade held various roles at Boehringer Mannheim (now part of Roche) and previously Sandoz (now part of Novartis). Mr. McDade chairs the board of directors of Aimmune Therapeutics (AIMT-nasdaq) and serves as a Trustee for the National Marine Sanctuary Foundation, a non-profit. Mr. McDade received a BA. in History from Dartmouth College and an M_BA. from the Harvard Business School.